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The vital role of the corticotropin-releasing factor (CRF) peptide family in the brain in coor-
dinating response to stress has been extensively documented. The effects of CRF are
mediated by two G-protein-coupled receptors, type 1 and type 2 CRF receptors (CRF1 and
CRF2).While the functional role of CRF1 in hormonal and behavioral adaptation to stress is
well-known, the physiological signiﬁcance of CRF2 remains to be fully appreciated. Accu-
mulating evidence has indicated that CRF2 and its selective ligands including urocortin 3
(Ucn 3) are important molecular mediators in regulating energy balance. Ucn 3 is the latest
addition of the CRF family of peptides and is highly selective for CRF2. Recent studies
have shown that central Ucn 3 is important in a number of homeostatic functions includ-
ing suppression of feeding, regulation of blood glucose levels, and thermoregulation, thus
reinforcing the functional role of central CRF2 in metabolic regulation. The brain loci that
mediate the central effects of Ucn 3 remain to be fully determined. Anatomical and func-
tional evidence has suggested that the ventromedial hypothalamus (VMH), where CRF2 is
prominently expressed, appears to be instrumental in mediating the effects of Ucn 3 on
energy balance, permitting Ucn 3-mediated modulation of feeding and glycemic control.
Thus, the Ucn 3-VMH CRF2 system is an important neural pathway in the regulation of
energy homeostasis and potentially plays a critical role in energy adaptation in response to
metabolic perturbations and stress to maintain energy balance.
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INTRODUCTION
Corticotropin-releasing factor (CRF) was discovered in 1981 by
Vale and colleagues at the Salk Institute (Vale et al., 1981). Its exis-
tencehadbeenhypothesized formany years prior to the 1981paper
characterizing the amino acid sequence of the peptide. Since then,
the importance of CRF family of peptides and receptors in stress
has steadily emerged. Extensive investigation has demonstrated
that CRF is critical in regulating the hypothalamic-pituitary-
adrenal (HPA) axis and in integrating endocrine, autonomic, and
behavioral responses to stressors (Perrin and Vale, 1999).
In addition to CRF, additional members of the CRF peptide
family including urocortins (Ucns) 1, 2, and 3 have been identiﬁed
in mammals, including humans (Vaughan et al., 1995; Hsu and
Hsueh, 2001; Lewis et al., 2001; Reyes et al., 2001). Accumulating
evidence suggests that the central actions of Ucn peptides may
account for some stress-related effects originally attributed to CRF
(Bale and Vale, 2004; Hashimoto et al., 2004; Venihaki et al., 2004;
Jamieson et al., 2006; Kuperman et al., 2010). For example, Ucn
1 appears to be involved in the later stage of the stress response
and adaptation to stress, while Ucns 2 and 3 may be involved in
attenuating the stress response (Ryabinin et al., 2012).
Additionally, the Ucns have been shown to be involved in
various physiological regulations including energy balance, car-
diovascular function, and behavioral modulation. Ucn 1, 2, and
3 all suppress feeding (Spina et al., 1996; Hashimoto et al., 2004;
Fekete et al., 2007), and deﬁciency in Ucn 2 improves glucose and
insulin homeostasis (Chen et al., 2006). Ucn 1 and 2 decrease car-
diac output and heart rate, and may be protective against ischemia
(Latchman, 2002; Bale et al., 2004; Hashimoto et al., 2004). Behav-
iorally, Ucn 1 plays a critical role in anxiety-like and depressive
behavior, and may be involved in the predisposition of alcohol
consumption (Vetter et al., 2002; Ryabinin et al., 2012). Ucn 2 may
be linked to depression but not anxiety (Ryabinin et al., 2012). Ucn
2 appears to inﬂuence social behavior, including aggression (Breu
et al., 2012), as mice deﬁcient in Ucn 2 are less aggressive and
prefer passive social interaction. Finally, Ucn 1 and CRF recep-
tors have been found in the auditory system (Graham et al., 2010)
and the peptide appears to be involved in the development and
maintenance of hearing (Vetter et al., 2002).
Urocortin 3 is the latest addition of the CRF family of peptides,
initially identiﬁed in the brains of humans and rodents (Hsu and
Hsueh, 2001; Lewis et al., 2001). Sequence analyses show that Ucn
3 is more closely related to Ucn 2 than Ucn 1 or CRF. Human and
mouse Ucn 3 share 40% homology with human and mouse Ucn
2, but only 21 and 18%, respectively, with human and mouse Ucn
1 and 32 and 26% with CRF (Lewis et al., 2001). Accumulating
evidence, as discussed below, has suggested that Ucn 3 is a critical
regulator in energy homeostasis.
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CORTICOTROPHIN-RELEASING FACTOR RECEPTORS
Two receptors have been identiﬁed for CRF: type 1 and type 2 CRF
receptors (CRF1 and CRF2), and amino acid sequence analysis has
shown that the two receptors share approximately 70% homol-
ogy (Perrin and Vale, 1999; Bale and Vale, 2004). Both CRF1 and
CRF2 are G-protein-coupled receptors with seven transmembrane
domains. These receptors signal predominantly through increased
cAMP production, but additional signaling pathways including
Ca2+, mitogen-activated protein kinase (MAPK), phospholipase
C, protein kinase B, and ion channels have also been shown to
couple to CRFRs (Kiang, 1997; Grammatopoulos, 2000; Brar et al.,
2002). The two receptors differ signiﬁcantly in their binding afﬁn-
ity forCRFpeptides and anatomical distributionwithin the central
nervous system (Chalmers et al., 1995; Van Pett et al., 2000; Hsu
and Hsueh, 2001; Lewis et al., 2001). Biochemical studies have
shown that CRF binds CRF1 with high afﬁnity while showing
modest afﬁnity for CRF2 (Bale and Vale, 2004). Ucn 1 binds both
CRF1 and CRF2 with equally high afﬁnity while Ucn 2 and Ucn 3
demonstrate preferential speciﬁcity for CRF2. However, while Ucn
2 may bind and stimulate CRF1 at high, pharmacological concen-
trations (Reyes et al., 2001), Ucn 3 is highly selective to CRF2 and
displays minimal afﬁnity for CRF1 (Hsu and Hsueh, 2001; Lewis
et al., 2001).
A circulating protein has been identiﬁed that binds CRF. It has
been suggested that the function of CRF binding protein (CRFBP)
is mainly to sequester CRF to reduce its HPA axis stimulation.
Levels of CRFBP are elevated in pregnancy to dampen the negative
effect of stress responses on the developing fetus (Goland, 1986).
In addition to CRFBP, a splice variant of CRF2 has been identiﬁed
that contains only the extracellular domain of the receptor and
shown to circulate, bind, and sequester CRF as well (Bon et al.,
1997; Chen et al., 2005). This splice variant also binds Ucn 1 but
has very low afﬁnity for Ucn 2 and 3 (Chen et al., 2005).
Anatomical mapping studies have demonstrated that CRF1 and
CRF2 have distinct distributions in the brain. CRF1 has a wide
distribution throughout the brain with high density in the medial
septal area, amygdala, and cerebellum (Chalmers et al., 1995; Van
Pett et al., 2000). CRF2 has three major variants that differ in their
N-terminal domains: CRF2(a), CRF2(b), and CRF2(c). In murine
brains, CRF2(a) is predominantly expressed in the hypothalamus,
lateral septum (LS), and dorsal raphe (Chalmers et al., 1995; Van
Pett et al., 2000). CRF2(b) is found predominantly in the periphery,
including in skeletal muscle, the gastrointestinal tract, and the
heart (Kanno, 1999; Wiley and Davenport, 2004; Porcher et al.,
2005; Tache and Bonaz, 2007). CRF2(c) is found only in the human
brain (Kostich et al., 1998).
The function of CRF1 has been closely associatedwith the stress
response, including the release of adrenocorticotropic hormone
(ACTH) from the anterior pituitary and behavioral adaptation to
stressors (Bale and Vale, 2004). The physiological role of CRF2,
however, is less deﬁned. Functional studies have shown this recep-
tor is involved in an array of homeostatic regulations, with most of
its actions regulating energy balance by modulating feeding, blood
glucose levels, and energy expenditure. This review will focus on
recent advances in the understanding of the physiological role of
CRF2 and Ucn 3 in the brain, particularly in the hypothalamus, in
the regulation of energy balance.
CRF2 IN ENERGY HOMEOSTASIS
Loss-of-function studies with CRF2 null mice and pharmacolog-
ical studies with CRF2 agonists both suggest that endogenous
CRF2 plays a physiological role in energy balance. Evidence from
several studies that examined ingestive behavior of CRF2 null
mice showed that endogenous CRF2 is required for the anorec-
tic effect of CRF peptide and is involved in control of the meal
size during active phase of eating and following acute exposure
to the stress (Bale et al., 2000; Coste et al., 2000; Pelleymounter
et al., 2000; Tabarin et al., 2007). Similarly, infusion of antisense
oligonucleotides to CRF2 mRNA attenuates both CRF and Ucn 1-
induced hypophagia and corticosterone secretion (Smagin et al.,
1998). Furthermore, CRF2 deletion protects mice from high-fat
diet-induced insulin resistance and glucose intolerance (Bale et al.,
2003). Taken together, it is clear that CRF2 is responsible for
mediating the effect of CRF family peptides on the suppression
of feeding and is involved in corticosterone secretion and glucose
homeostasis.
In addition to feeding, CRF2 is involved in regulating energy
expenditure. CRF2 knockout (KO) mice have more active
metabolism and lose heat faster than wildtype (WT) mice (Car-
lin et al., 2006), suggesting an exaggerated level of sympathetic
activity. Moreover, CRF2 KO mice have higher brown adipose tis-
sue (BAT) temperature and, when given a choice between room
temperature and warm areas, prefer warmer areas more than WT
mice (Carlin et al., 2006). The KO mice also have higher oxy-
gen consumption and carbon dioxide production and reduced
respiratory exchange rate (Carlin et al., 2006), indicating a pref-
erence in fatty acid oxidation over carbohydrate utilization in the
KO mice. It was suggested that a lack of functional CRF2 leads
to elevated CRF1 activity, which consequently increases sympa-
thetic nervous system (SNS) activity to promote lipolysis (Carlin
et al., 2006). This hypothesis appears to disagree with pharmaco-
logical studies, as activation of central CRF2 (discussed below),
in most cases, results in increased SNS activity. This apparent
discrepancy may result from a number of possibilities including
compensatory mechanisms due to total body KO of the recep-
tor as compared to acute, local stimulation of the receptor in the
brain. Obviously more studies are needed to further elucidate this
issue.
Leptin, a hormone secreted by adipocytes, is a potent appetite
suppressant (Uehara et al., 1998; Zigman, 2003). A number of
studies suggest that its effect on feeding may involve the CRF
receptor system. Though leptin treatment greatly decreases food
intake, when co-administered with a non-selective CRF receptor
antagonist, food intake remains at a nearly normal level (Gard-
ner et al., 1998), suggesting the CRF system is a downstream
target of leptin in the brain. However, this notion was recently
challenged by a study (Harris, 2010) demonstrating that CRF2 is
not essential for the effects of leptin on energy balance, includ-
ing feeding and body weight regulation. Again this discrepancy
may be due to the nature of global CRF2 KO, which potentially
results in functional compensation such as exaggerated CRF1
activity in these mice (Carlin et al., 2006). Therefore, central or
speciﬁc brain area deletions of CRF2 may be necessary to fur-
ther evaluate the interaction of leptin and the CRF system in the
brain.
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UROCORTIN 3
ANATOMICAL LOCATION OF Ucn 3
Urocortin 3 is found both in the periphery and in the brain. In the
periphery, it is expressed in the digestive tract, muscle, thyroid and
adrenal glands, pancreas, heart, spleen, and skin (Hsu and Hsueh,
2001; Lewis et al., 2001). In the brain, neurons expressing Ucn 3
are concentrated in themedial amygdala (MeA) andhypothalamus
(Lewis et al., 2001; Li et al., 2002). In the hypothalamus, the major
Ucn 3 cell population is near the rostral perifornical hypothala-
mic area (rPFA; Li et al., 2002). Speciﬁcally, Ucn 3-positive cells are
gathered around the fornix lateral to the paraventricular nucleus of
the hypothalamus (PVH). This group extends rostrally and stays
close to the fornix into the posterior part of the bed nucleus of
the stria terminalis (pBNST) and medially into the anterior parvi-
cellular part of the PVH (PVHap). A recent study has elucidated
anatomical heterogeneitywithin this hypothalamicUcn 3 cell pop-
ulation, as neurons of the rostral part (PVHap/pBNST) project to
the ventromedial hypothalamus (VMH), and those of the caudal
part, residing in the rostral perifornical hypothalamus (rPFH),
projects to the LS (Chen et al., 2011). A second group of Ucn 3-
positive cells is found in the median preoptic nucleus (MnPO; Li
et al., 2002). In the forebrain, prominent Ucn 3 nerve ﬁbers and
terminals are found in the VMH, LS, MeA, and BNST (Li et al.,
2002). These areas also express high levels of CRF2 (Chalmers
et al., 1995; Van Pett et al., 2000). This overlap of Ucn 3 and CRF2
distribution and the high afﬁnity of the peptide for the receptor
strongly suggest that Ucn 3 is an endogenous ligand for CRF2 in
these brain areas.
METABOLIC EFFECTS OF Ucn 3
All 3 Ucns bind CRF2 and may each be responsible for some of the
receptor’s energy homeostatic effects. However, Ucn 3 alone has
myriad metabolic effects.
Feeding
Central administration, KO, and overexpression studies reveal a
role of Ucn 3 in the regulation of feeding. When directly infused
into the lateral ventricles, Ucn 3 decreases nocturnal food and
water intake in a dose dependent manner, primarily due to
decreased meal frequency, and this effect was eliminated with
concomitant CRF2 antagonist treatment (Fekete et al., 2007). The
anorectic effect of Ucn 3 is not due to distaste for food, as no con-
current taste aversion develops (Fekete et al., 2007). Consistent
with pharmacological evidence, genetic Ucn 3 deﬁciency appears
to lead to overeating. Though Ucn 3 KO mice have similar body
weights toWTanimals,KOmice eatmore andhave increased accu-
mulated food intake. Similar to CRF2 null mice, Ucn 3 KO mice
exhibit elevated nocturnal feeding, when greatest spontaneous
food intake naturally occurs (Chao et al., 2012). Taken together,
it is clear that Ucn 3 in the brain functions as a potent anorec-
tic agent. However, a study that used genetic overexpression of
Ucn 3 challenged this notion. Under regular chow-fed condition,
mice with overexpression of Ucn 3 (Ucn3+) have higher body
mass-adjusted food intake than WT and are heavier than WT con-
trols due to increased lean body mass (Jamieson et al., 2011). On
the other hand, Ucn3+ mice do not gain as much weight as WT
mice when fed with a high-fat diet (Jamieson et al., 2011). This
result seems to be in line with the notion of Ucn 3 as an anorectic
agent. The discrepancy between different mouse models can be
due to a number of possibilities including the ramiﬁcation of Ucn
3 overexpression both in the brain as well as in the periphery.
A temporally and spatially controlled viral approach to overex-
press Ucn 3 in the rPFH shows that Ucn 3 in the rPFH does not
modulate food intake (Kuperman et al., 2010), as mice with Ucn
3 overexpression in the rPFH ingest consume similar amount of
food as control mice (Kuperman et al., 2010). The rPFH-speciﬁc
Ucn 3-overexpressing mice show a trend toward being heavier, but
retain the same fat–lean mass percentages as control mice (Kuper-
man et al., 2010). As mentioned above, Ucn 3 cells in the rPFH
project mainly to the LS with minimal projection to the VMH.
Therefore, it is reasonable to assume that CRF2 in the LS will be
overstimulated in this mouse model. Interestingly, a number of
studies have shown that CRF2 in the LS is involved in suppression
of food intake (Wang and Kotz, 2002; Bakshi et al., 2007). Cur-
rently, it is unclear as to why overexpression of Ucn 3 in the rPFH
fails to suppress feeding. The expression of CRF receptor has been
shown to be subject to ligand-induced receptor down-regulation
(Rabadan-Diehl et al., 1996; Eghbal-Ahmadi et al., 1997). It is con-
ceivable that chronic elevated Ucn 3 input to the LS in Ucn 3 rPFH
overexpression mice may lead to alteration in CRF2 expression
and consequently reduced response to Ucn 3 stimulation in the
LS. Thus, it is possible that acute stimulation of CRF2 in the LS
suppresses feeding, but chronic stimulation of CRF2 in the LS in
mice with Ucn 3 overexpression in the rPFH may lead to negative
feedback to balance the effect of CRF2 in feeding. Clearly, more
studies are needed to elucidate the effect of Ucn 3 overexpression
in the regulation of food intake. In addition to Ucn 3, Ucn 1 neu-
rons in the midbrain Edinger–Westphal nucleus have been shown
to innervate the LS (Kozicz et al., 1998; Bittencourt et al., 1999).
Therefore, both Ucn 1 and 3 may contribute to the effect of CRF2
on feeding in the LS.
The mechanism of Ucn 3-induced anorexia has not been
directly studied. Central administration of CRF2 agonists, includ-
ing Ucn 3, have been shown to inhibit gastric emptying (Martinez
et al., 2004; Stengel and Tache, 2009), and elevate blood glucose
levels (Jamieson et al., 2006; Chen et al., 2010). Both reduced gut
motility and hyperglycemia have been shown to induce satiation
and reduce feeding (Ritter, 2004; Cummings and Overduin, 2007;
Wolfgang et al., 2007; Cha et al., 2008). Therefore, multiple mech-
anisms are potentially involved in mediating the anorectic effect
of Ucn 3 in the brain.
Energy homeostasis
Similarly to CRF2, Ucn 3 is also involved in energy expendi-
ture. Central administration of Ucn 3 increases motor activity
(Ohata and Shibasaki, 2004). Similarly, transgenic Ucn 3 over-
expression mice (Ucn3+) have an increased respiratory exchange
ratio and increased motor activity in their home cages (Jamieson
et al., 2011). Furthermore, mice with Ucn 3 overexpressed in the
rPFH had an increased respiratory exchange ratio and elevated
heat production (Kuperman et al., 2010). This is consistent with
the notion that Ucn 3 is involved in SNS activity and energy home-
ostasis. Ucn 3 KO mice, on the other hand, do not show the same
pattern; there are no differences in oxygen consumption, heat
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production, or activity levels (Chao et al., 2012). Therefore, KO of
Ucn 3 in speciﬁc brain areas may provide better insight into the
role of speciﬁc populations of Ucn 3 cells in the brain in energy
expenditure.
Glucose homeostasis
Several studies have revealed a complex role of Ucn 3 in glucose
homeostasis. Though adult Ucn 3 KO mice fed a chow diet show
no differences in glucose tolerance and insulin sensitivity com-
pared to WT mice (Li et al., 2007), Ucn 3 KOs have lower basal
insulin levels and show a greater rebound in blood glucose levels
after the initial hypoglycemia during an insulin tolerance test (Li
et al., 2007; Chao et al., 2012). Furthermore, under high-fat diet
feeding, adult KO mice are more metabolically resilient. The Ucn
3 KO mice have lower plasma insulin and blood glucose concen-
trations than WT mice, remain sensitive to insulin and do not
develop glucose intolerance and liver steatosis with the same fre-
quency of WT mice (Li et al., 2007). Moreover, aged KO mice show
better glucose homeostasis than age-matched WT mice (Li et al.,
2007). Overall, Ucn 3 deﬁciency appears to protect the mice from
metabolic disorders caused by high-fat feeding. It is noteworthy
that Ucn 3 is expressed in pancreatic β cells and has been shown to
play a critical role as a local regulator in insulin secretion (Li et al.,
2003). Thus, it is likely that Ucn 3 in both the brain and in the
periphery, especially in the pancreas, contribute to the phenotypes
observed in Ucn 3 null mice.
On the other hand, Ucn3+ transgenic mice also appear to be
protected against excessive metabolic challenge, having decreased
fed and fasting blood glucose levels and increased tolerance to
glucose when challenged in a glucose tolerance test (Jamieson
et al., 2011). Fasting insulin levels in Ucn3+ mice are also lower
than that in WT mice, though an insulin tolerance test shows
no differences in insulin sensitivity (Jamieson et al., 2011). When
challenged with a high-fat diet, Ucn3+ mice fare better than the
WT littermates, maintaining normal body weight and low blood
glucose levels, but display comparable insulin sensitivity to theWT
control mice (Jamieson et al., 2011). Though Ucn3+ mice show
improved glucose homeostasis and insulin sensitivity, overexpres-
sion of Ucn 3 in the rPFH produces the opposite effect; rPFH
Ucn 3-overexpressing mice show reduced insulin sensitivity and
increases basal insulin levels, however they show no difference in
glucose tolerance (Kuperman et al., 2010).
While genetic KO of Ucn 3 appears to have metabolic protective
qualities, the effect of Ucn 3 overexpression is unclear. Full body
overexpression of Ucn 3 seems protective, while targeted over-
expression within the rPFH appears metabolically detrimental.
Interestingly, Ucn3+ mice have lower fasting blood glucose levels
and higher energy intake under basal conditions (Jamieson et al.,
2011). As stated earlier, CRF2 is expressed abundantly in a num-
ber of peripheral tissues including skeletal muscle (Perrin et al.,
1995; Stenzel et al., 1995; Wiley and Davenport, 2004; Porcher
et al., 2005; Kuperman et al., 2011). Stimulation of muscle CRF2
has been shown to promote thermogenesis (Solinas et al., 2006).
Moreover, muscle CRF2 is involved in regulating skeletal muscle
mass (Hinkle et al., 2003) and consistent with this notion, Ucn3+
mice have increased muscle mass (Jamieson et al., 2011). Thus, it
is conceivable that the improved glucose homeostasis of Ucn3+
mice is due, at least in part, to stimulation of muscle CRF2 by
ectopic overexpression of Ucn 3 in the periphery.
Thermoregulation
Functional studies have shown that Ucn 3 is involved in ther-
moregulation, potentially acting on brown fat. It was found
that Ucn 3 induced a signiﬁcant increase in body temperature,
from 37.2 to 38.6◦C (99.0 to 101.5◦F), when injected into the
lateral ventricles of rats (Telegdy et al., 2006). Temperature grad-
ually decreased after peaking 2 h after Ucn 3 administration,
but remained signiﬁcantly elevated for a total of 4 h (Telegdy
et al., 2006). Moreover, pretreating animals with CRF2 but not
CRF1 antagonists completely blocked Ucn 3-induced hyperther-
mia, indicating that the pyrogenic action of Ucn 3 is mediated
by CRF2 (Telegdy and Adamik, 2008). Noraminophenazone, a
cyclooxygenase inhibitor, simultaneously applied with Ucn 3
also prevented the temperature increase and also attenuated the
increase when administered 30 min after Ucn 3 treatment (Telegdy
et al., 2006). This indicates that the arachidonic acid cascade form-
ing prostaglandin is a downstream target of central Ucn 3 and
CRF2 system in thermoregulation. Currently, the brain loci that
may mediate the effect of Ucn 3 in body temperature remain elu-
sive. The MnPO is known to be a center for thermoregulation
and expresses high concentrations of the prostaglandin receptor
EP3 (Morrison et al., 2008). It has been shown that prostaglandins
play an important role in the MnPO through EP3 to regulate body
temperature (Morrison et al., 2008). Furthermore, the presence of
a group of Ucn 3 cells in the MnPO (Li et al., 2002) suggests that
Ucn 3 might be involved in MnPO mediates pyrogenic effects.
REGULATION OF Ucn 3 EXPRESSION IN THE BRAIN
The expression of Ucn 3 in the brain has been determined in
a number of stress paradigms and metabolic challenges. It was
found that restraint stress rapidly elevates Ucn 3 gene expres-
sion in the MeA and that the elevated Ucn 3 mRNA levels
return to basal levels 4 h after the stress (Jamieson et al., 2006).
Restraint stress also increases Ucn 3 mRNA levels in the rPFA but
with a slower time course compared to that of the MeA (Veni-
haki et al., 2004; Jamieson et al., 2006). Adrenalectomy greatly
elevatesUcn3 expression in the rPFA,while corticosterone replace-
ment returns the expression to a basal level (Jamieson et al.,
2006). This result indicates that corticosterone may be involved in
stress-mediated Ucn 3 gene expression in the rPFA. Hemorrhage
decreases Ucn 3 expression in the MeA after 30 min, and 48 h
of food deprivation also decreases Ucn 3 expression in the MeA
(Jamieson et al., 2006).
The expression of Ucn 3 has also been examined in genetically
obese rodent models. Food deprivation increases Ucn 3 mRNA
expression in the dorsal part of the medial amygdala (MeD) in
obese Fa/Fa Zuker rats and has no effect on Ucn 3 expression
in the rPFH (Poulin et al., 2012). In contrast, lean Fa/? rats show
increasedUcn 3 expression in the rPFHbut not theMeD after food
deprivation (Poulin et al., 2012). Ucn 3 mRNA expression returns
to normal after 24 h of refeeding (Poulin et al., 2012). In ob/ob
obese mice, Ucn 3 expression is signiﬁcantly reduced in the MeA
(Figure 1; Li and Vale, 2002), and leptin treatment reverses Ucn
3 expression in this area. Interestingly, pair-feeding in ob/ob mice
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FIGURE 1 | Representative darkfield photomicrographs showing
Ucn 3 mRNA expression (white clusters) in a wildtype mouse
(A), an ob/ob obese mouse (B), and an ob/ob mouse treated with
leptin (0.1 mg/kg/day for 2 days) (C). (D) Summary of Ucn 3 mRNA
levels in the MeA ofWT and Ob/ob obese mice treated with vehicle or
leptin. The Ucn 3 mRNA levels in an additional group of Ob/ob
mice that was paired-fed were also determined. Different letters
represent statistical signiﬁcance: p < 0.05. MeApd, medial
nucleus of amygdala, posterodorsal part; opt, optic tract. Scale
bar = 20 μm.
failed to modulate Ucn 3 expression in the MeA. These results
indicate that Ucn 3 expression in the MeA is regulated by lep-
tin. Taken together, these studies further support the notion that
endogenous Ucn 3 in the brain is sensitive to metabolic signals and
energy status and potentially plays an important role in regulating
energy homeostasis.
THE VENTROMEDIAL HYPOTHALAMUS
The anatomical distribution of CRF2 in the brain has provided
important insight into possible areas that mediate the effects of
CRF2 in energy balance. The VMH has received signiﬁcant atten-
tion due to its abundant expression of CRF2 and well-known
role in regulating energy homeostasis, feeding, and blood glucose
levels.
The VMH is parceled on cytoarchitectonic grounds into three
major divisions: dorsomedial (VMHdm), central, and the ven-
trolateral (VMHvl) parts (Gurdjian, 1927). The VMH volume
is larger in males compared with females, and this difference is
largely accounted for by the VMHvl, which in females is signif-
icantly smaller than that in males (Dugger et al., 2007). Further,
VMHvl in female rats express higher levels of estrogen receptors
than that in males, and has been shown to play a critical role in
regulating lordosis behavior in females (Flanagan-Cato, 2011) and
aggressiveness in males (Lin et al., 2011).
The VMH has long been considered a critical brain area in
the regulation of energy homeostasis. Lesion of the VMH results
in hyperphagia, hyperinsulinemia, reduction of SNS activity,
increase of fat mass, and reduction of energy expenditure that ulti-
mately leads to storage of excess of energy and obesity (Bernardis
and Frohman, 1971; Inoue et al., 1977; Cox and Powley, 1981;
Niijima et al., 1984; Sakaguchi et al., 1988; Rufﬁn and Nicolaidis,
1999; King, 2006). Conversely, stimulation of the VMH results in
predominately opposite phenotypes including inductionof satiety,
increase in SNS activity, lipolysis, and thermogenesis (King, 2006).
In recent years, the importance of theVMH in energy homeostasis
has been further ascertained with the aid of improved molecular
tools and mouse genetics (Sternson et al., 2005; King, 2006; Chao
et al., 2012). For example, mice with VMH-speciﬁc deletion of a
number of genes including the leptin receptor (Dhillon et al., 2006;
Bingham et al., 2008), estrogen receptor α (Musatov et al., 2006,
2007), and vesicular glutamate transporter-2 (VGLUT2; Tong
et al., 2007) result in a number of abnormalities such as increased
feeding, reduced energy expenditure, impaired glucose homeo-
static regulation, and obesity. Moreover, mice bearing a deletion
of steroidogenic factor 1 (SF1), a transcription factor involved in
steroidogenesis that is highly enriched in the VMH, show similar
phenotypes in energy homeostasis and are obese (Luo et al., 1994;
Sadovsky et al., 1995; Shinoda et al., 1995).
EXPRESSION OF CRF2 IN THE VMH
The VMH is one of the brain areas with prominent CRF2 expres-
sion (Chalmers et al., 1995; Van Pett et al., 2000). The expression is
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concentrated in the dorsomedial part of the nucleus with decreas-
ing density toward the ventrolateral division of the VMH. The
expression of CRF2 in the VMH has been shown to be sensitive
to energy status and stress. For example, leptin injection increases
and fasting decreases CRF2 expression in the VMH and ob/ob
mice or Fa/Fa Zucker rats have lower CRF2 in theVMH compared
to WT controls (Richard et al., 1996; Makino et al., 1998, 1999;
Nishiyama et al., 1999). Furthermore, restraint stress and gluco-
corticoids increase CRF2 levels in the VMH (Makino et al., 1998,
1999). Thus, these data support the notion that CRF2 in the VMH
is important in regulating energy balance.
Currently, detailed neurochemical phenotypes of CRF2-
positive cells within the VMH remain unclear. Several proteins
have been found to be expressed in the VMH including SF1, pitu-
itary adenylate cyclase-activating polypeptide, the leptin receptor,
and VGLUT2 (Fei et al., 1997; Elmquist et al., 1998; Ziegler et al.,
2002; Segal et al., 2005; Kurrasch et al., 2007). It has been shown
that CRF2 extensively colocalizes withVGLUT2 in theVMH(Chen
et al., 2010). VGLUT2 mediates glutamate uptake into synaptic
vesicles of excitatory neurons (Fremeau et al., 2001; Herzog et al.,
2001; Takamori et al., 2001) and has been used extensively as a
marker for excitatory glutamatergic neurons. The colocalization
of CRF2 and VGLUT2 suggests that CRF2 is expressed predomi-
nately in excitatory neurons in theVMH.Asmentioned above, SF1
is a nuclear receptor that regulates the transcription of key genes
involved in sexual development and reproduction (Parker et al.,
2002). In adults, SF1 expression is speciﬁcally conﬁned to the
VMH (Parker et al., 2002). In SF1 null mice, CRF2 mRNA expres-
sion is nearly undetectable in theVMH (Luo et al., 1994; Sadovsky
et al., 1995; Shinoda et al., 1995), suggesting CRF2 is expressed in
SF1 cells in the VMH. Consistent with this notion, it was found
that more than 90% of CRF2 neurons in the dorsomedial part of
the nucleus are also SF1-positive (Figure 2)with less colocalization
of these two materials in the VMHvl (Digruccio et al., 2007).
CRF LIGANDS INPUT INTO THE VMH
The anatomical distribution of a number of the CRF family pep-
tides has been determined, and it was found that CRF and Ucn
1-expressing neurons provide minor innervation to the VMH
(Swanson et al., 1983; Kozicz et al., 1998; Bittencourt et al., 1999).
Interestingly, low levels of Ucn 1-immunoreactivity have been
detected in cells in the VMH (Kozicz et al., 1998), suggesting Ucn
1 may be a local factor in the nucleus. Although Ucn 2 ﬁber dis-
tribution has not been determined, Ucn 2-positive cells have been
found in a number of brain areas including the magnocellular
part of the PVH, locus ceruleus, and facial motor nucleus (Reyes
et al., 2001), and none of these areas provide extensive projection
into the VMH (McBride and Sutin, 1977; Luiten and Room, 1980;
Berk and Finkelstein, 1981; Kita and Oomura, 1982; Zaborszky,
1982; Fahrbach et al., 1989; Chen et al., 2011). Compared to other
CRF innervations, Ucn 3 neuronal ﬁbers abundantly innervate
the VMH (Li et al., 2002). Similar to the expression of CRF2 in
the VMH, Ucn 3-positive axonal ﬁbers and terminals concentrate
in the dorsomedial part of the VMH with reduced density toward
the ventrolateral part of the nucleus (Li et al., 2002). As stated
above, Ucn 3 neurons in the PVHap provide the major Ucn 3
afferent input into the VMH and Ucn 3 cells in the pBNST and
FIGURE 2 | (A) Darkﬁeld photomicrograph showing CRFR2 mRNA signal
revealed by in situ hybridization in the basal hypothalamic area of a
transgenic mouse expressing Cre recombinase (Cre) and enhanced yellow
ﬂuorescent protein (EYFP) in SF1-positive cells. Note that CRFR2 mRNA
hybridization signal (white clusters) was abundant in the dorsomedial part
of the VMH (VMHdm). (B) Bright ﬁeld photomicrograph of the same area in
(A) showing SF1-positive cells, revealed by immunostaining with anti-green
ﬂuorescent protein antibody (darkbrown precipitates) in the VMH. (C) High
magniﬁcation of boxed area in (A) showing colocalization of CRFR2 (black
dot clusters) and SF1 (brown precipitates) in the VMH. ARH, arcuate
nucleus of hypothalamus; V3, third ventricle; VMHc, central part of the
VMH; VMHdm, dorsomedial part of the VMH; VMHvl, ventrolateral part of
the VMH. Scale bar = 50 μm (B), 20 μm (C).
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the MeA comparatively provide moderate input into the nucleus
(Chen et al., 2011). Interestingly, Ucn 3 cells in the rPFH, imme-
diately caudal and adjacent to the PVHap, provide minimal Ucn 3
afferent input into the VMH and instead send strong innervation
into the LS.
Neural inputs into the PVHap and MeA have been studied
(Sawchenko and Swanson, 1983; Swanson and Petrovich, 1998;
Uehara et al., 1998; Maras and Petrulis, 2010; Carrillo et al., 2011;
Northcutt and Lonstein, 2011; Radley and Sawchenko, 2011; Van
Hover et al., 2011). In general, the two brain areas receive simi-
lar afferent input from a number of brain regions including the
septal nuclei and amygdala. However, a few subtle but signiﬁ-
cant exceptions should be noted. The PVHap receives prominent
inputs from the hypothalamus, cortex, and brainstem, whereas
the MeA receives strong inputs from the bed nucleus of the acces-
sory olfactory tract and nucleus of stria medullaris. These ﬁndings
suggest Ucn 3 cells in the PVHap receive inputs that transmit vis-
ceral and autonomic information while the Ucn 3 cell group in the
MeA receives afferents that relay olfactory information. Thus, it
is conceivable that central Ucn 3 may serve as a common peptide
neurotransmitter in the various neural pathways that convey infor-
mation from assorted neural signals into the VMH to coordinate
the regulation of energy homeostasis.
FUNCTION OF CRF2 IN THE VMH
When the function of CRF2 in the VMH was ﬁrst assessed by
injecting Ucn 1 into the VMH, it was found that the peptide
potently suppresses food intake (Ohata et al., 2000). However,
because CRF1 has been suggested to be expressed in the VMH
(Cheng et al., 2007) and Ucn 1 has equally high afﬁnity for both
CRF1 and CRF2 (Vaughan et al., 1995), it remains possible that
CRF1 may also contribute to the anorectic effect of Ucn 1 in the
VMH. More recently, when the CRF2-selective ligand Ucn 3 was
identiﬁed (Lewis et al., 2001), the function of CRF2 in the VMH
was re-examined by site-speciﬁc injection of Ucn 3 into the VMH
(Fekete et al., 2007; Chen et al., 2010). Consistent with the Ucn 1
injection study, stimulation of CRF2 by Ucn 3 in the VMH signiﬁ-
cantly suppresses feeding. Moreover, stimulation of CRF2 in other
regions including the PVH, amygdala, and the lateral hypotha-
lamus fails to modulate feeding (Ohata et al., 2000; Fekete et al.,
2007; Chen et al., 2010), reinforcing the notion that VMH CRF2
plays a critical role in mediating the effect of CRF peptides in
suppressing food intake.
In addition to appetite suppression, activation of CRF2 in the
VMH results in rapid elevation of blood glucose levels (Chen et al.,
2010). This is consistent with the function ofVMHneurons in glu-
cose homeostasis, as VMH neurons have been suggested to play
an important role in regulating glucose levels via glucose sensing,
and modulating glucose production in peripheral tissues (Kang
et al., 2004; Levin et al., 2004). On the other hand, it has been
shown that stimulation of CRF2 in the VMH suppresses insulin-
induced release of glucagon and epinephrine (McCrimmon et al.,
2006), indicating thatVMHCRF2 exerts a negative control over the
counterregulatory response (CRR). Taken together, it is possible
that the functional role of CRF2 in the VMH in glucose home-
ostasis is context dependent. When blood glucose is low as a result
of hyperinsulinemia, CRF2 in the VMH negatively regulates the
CRR response. On the other hand, under normoglycemia, CRF2
induces acute hyperglycemia to facilitate fuel mobilization per-
haps in response to stress. We have also found that CRF2-positive
neurons in the VMH are sensitive to glucose, as high glucose in-
hibits and low glucose stimulates the neuronal activity (Digruccio
et al., 2007).
Type 2 CRF receptor has been shown to modulate the HPA axis.
For example, CRF2 KO mice display altered HPA hormonal secre-
tion, and central Ucn 3 injection facilitates stress-induced ACTH
secretion (Jamieson et al., 2006). On the other hand, activation
of CRF2 in the VMH fails to modulate HPA hormone secretion
(Chen et al., 2010), indicating that the receptor in the VMH is not
essential for central Ucn 3-induced HPA activation. Thus, CRF2-
positive brain loci that are important for modulation of the HPA
axis remain to be determined.
PHYSIOLOGICAL ROLE OF CRF2 IN THE VMH
To probe the physiological role of endogenous CRF2 in the VMH,
VMH-speciﬁc CRF2 knockdown mice were generated by injec-
tion of a lentiviral vector expressing CRF2 small hairpin RNA
(shRNA; Chao et al., 2012). Mice injected with CRF2 shRNA dis-
played signiﬁcantly reduced CRF2 mRNA levels and gain more
weight, mostly in white fat, than control mice. Furthermore, sim-
ilar to Ucn 3 null mice, mice with reduced CRFR2 in the VMH
exhibited elevated basal food intake and ate more than the con-
trol mice after overnight fasting. This result indicates that CRF2
in the VMH serves as a brake to facilitate the cessation of feeding.
This study suggests that CRF2 in the VMH plays a critical role in
mediating the effect of central Ucn 3 in energy balance.
In addition to elevated feeding, mice with decreased expres-
sion of CRF2 in the VMH display reduced lipolysis and increased
adiposity in white fat (Chao et al., 2012). This is likely due to
reduced SNS activity, as the VMH has been shown to regulate
lipolysis via sympathetic outﬂow (Kumon et al., 1976; Takahashi
and Shimazu, 1981; Rufﬁn and Nicolaidis, 1999). Interestingly,
CRF2 knockdown in the VMH has no major impact in heat pro-
duction or uncoupling protein 1 expression in BAT, suggesting that
CRF2 in the VMH does not signiﬁcantly modulate thermogenesis
in BAT. This result appears to disagree with earlier reports that
VMH is involved in regulating thermogenesis in BAT (Perkins
et al., 1981; Kim et al., 2011). Anatomical studies have demon-
strated a compartment-speciﬁc organization of innervation of
different peripheral organs, as abdominal fat and subcutaneous
fat are innervated by different neural pathways (Kreier et al., 2002,
2006). It is possible that CRF2-positive neurons are a subpopula-
tion of cells in the VMH that regulate SNS outﬂow to white fat
without signiﬁcant functional impact on BAT. Heterogeneity of
VMH neurons has been reported as overlapping but distinct sub-
population of neurons in the VMHvl that are critical in regulating
ﬁghting and mating (Lin et al., 2011).
Consistent with the function of CRF2 in regulating blood glu-
cose levels, mice with reduced CRF2 expression in the VMH show
improved glucose homeostasis compared to control mice (Chao
et al., 2012). Moreover,micewithCRF2 knockeddown in theVMH
exhibit an exaggerated rebound in blood glucose levels compared
to control mice after the initial hypoglycemic response to insulin
challenge. This result agrees with the study by McCrimmon et al.
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(2006), who found that injection of Ucn 3 into the VMH sup-
presses the hypoglycemia-induced CRR response. Taken together,
these studies strongly argue that CRF2 is a critical molecular
mediator in VMH regulation of glucose homeostasis.
NEUROCIRCUITS UNDERLYING THE EFFECT OF VMH
Tounderstand howVMHCRF2 neurons regulate output functions
and to describe an anatomical link between these neurons and the
SNS, it is necessary to determine their axonal projections to iden-
tify downstream targets in the brain. A number of anterograde
tracing studies utilizing different tracers have been performed to
evaluate the projections of VMH neurons. Generally, it was found
that VMH neurons project extensively to neighboring hypotha-
lamic nuclei including the anterior and paraventricular nucleus,
BNST, and periaqueductal gray (PAG; Saper et al., 1976; Can-
teras et al., 1994). These anatomical studies raise an interesting
dilemma. Although it is clear that VMH activity modulates SNS
activity, these studies failed to observe directVMHefferents within
well-known autonomic centers in the brainstem. Thus, it was con-
cluded that the VMH likely modulates SNS activity indirectly by
ﬁrst projecting to a relay center such as the PAG.
Recently, using a conditional viral tracing approach, we have
found thatVMH neurons project to a number of important brain-
stem autonomic centers including the parabrachial nucleus, C1
catecholaminergic cell group in the rostral ventrolateral medulla,
and the nucleus of solitary tract (Lindberg et al., 2011). Moreover,
we have used the same approach to ﬁnd that CRF2-positive cells
in the VMH show similar axonal projections to these brainstem
areas (Figure 3; Lindberg et al., 2011). These studies demonstrate
that VMH neurons, including cells that express CRF2, can poten-
tially modulate SNS activity by direct projections to brainstem
autonomic centers.
CONCLUSION
The function of CRF peptides and their receptors in coordinating
hormonal, neuronal, and behavioral responses to stress is well rec-
ognized. Pharmacological studies have determined that the CRF2
receptors are involved in the regulation of energy homeostasis.
Recent studies using various genetic mouse models and molecu-
lar tools have further ascertained the critical role of CRF2 and its
selective ligands, including Ucn 3, in feeding, blood glucose regu-
lation, SNS output, and peripheral metabolism. Moreover, CRF2
in the VMH mediates most, if not all, of the effects of central Ucn
3 on energy homeostasis.
It is clear that conﬂicting results have been observed between
whole body and region- or tissue-speciﬁc KO or overexpression
mouse models. Furthermore, several studies have demonstrated
that anatomical or even functional heterogeneity exists within
a seemingly single Ucn 3 cell population in the hypothalamus.
Thus, a more detailed understanding of the physiological func-
tion of CRF2 and its selective ligands in the brain will be aided by
brain region-speciﬁc transgenic animalmodels permittingmanip-
ulation of ligand or receptor expression. Study of such models
will provide insight into the speciﬁc roles of CRF2 in modulating
metabolic functions.
Regulation of energy balance under diverse challenges includ-
ing stress, starvation, or high-fat diet requires numerous adaptive
FIGURE 3 | (A) Darkﬁeld photomicrograph showing the injection site
(green circle) of an adenoviral vector encoding Cre-regulated expression of
farnesylated green ﬂuorescent protein (GFPf) delivered into the VMH of a
CRFR2-Cre mouse. The expression of GFPf is normally silenced due to a
Cre-regulated transcription block sequence inserted upstream of GFPf
reporter cassette. In the presence of Cre, the transcription block sequence
is removed to allow GFPf to be expressed in Cre-positive cells. (B) Darkﬁeld
photomicrograph depicting the distribution of VMH CRFR2-positive ﬁbers
(golden staining) within the rostral ventrolateral medulla (RVLM). ARH,
arcuate nucleus of hypothalamus; MARN, magnocellular reticular nucleus;
ME, median eminence; Py, pyramidal tract; Tu, tuberal nucleus; V3, third
ventricle; VII, facial nucleus; VMHdn, dorsomedial part of the ventromedial
nucleus of hypothalamus. Scale bar = 50 μm.
mechanisms in both central and peripheral tissues. It is now
clear that central CRF2 and Ucn 3 are involved in this regula-
tion, as the expression of the receptor and ligands are closely
regulated under these challenges. It is thus conceivable that dys-
regulated CRF2 or ligand function potentially cause or exacerbate
metabolic perturbations. This hypothesis can be easily tested with
the above mentioned rodent models to determine the functional
role of the CRF2 system in metabolic diseases. Moreover, a better
understanding of the molecular mechanisms by which various
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stressors or metabolic signals regulate the expression and/or func-
tion of CRF2 and its ligand will provide signiﬁcant insight into
the potential role of the CRF family and its receptors in the
pathophysiology of metabolic disorders including obesity and
diabetes.
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